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Abstract To assess the putative role of mitochondrial uncou-
pling protein 2 (UCP2) during perinatal development, its
expression was analysed in mice and rats. Expression was
detected in a large range of foetal tissues. A unique develop-
mental pattern of UCP2 expression was found in liver, where the
level of UCP2 mRNA was about 30-fold higher in foetuses than
in adults (mice data), and started to decline immediately after
birth. Neither UCP1 nor UCP3 mRNA was expressed in foetal
liver. As in adult liver, immunohistochemical analysis suggested
exclusive localisation of UCP2 in the monocyte/macrophage
cells. Our results indicate a role of UCP2 in haematopoietic
system development.
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1. Introduction
The e⁄ciency of energy conversion in mammalian mito-
chondria may be controlled by at least three distinct uncou-
pling proteins (UCPs) belonging to the gene family of mito-
chondrial ion transporters [1]. UCP1, the ¢rst UCP to be
identi¢ed, is exclusively located in brown adipocytes [2,3]. It
increases proton conductivity of the inner mitochondrial
membrane, and enables regulatory heat production at the ex-
pense of ATP synthesis [4]. UCP2 and UCP3, which have
been described only recently [5^9], also collapse the mitochon-
drial membrane potential, suggesting that all UCPs function
in a similar manner. UCP2 is expressed in many human and
rodent [5^9] tissues, with the highest levels observed in white
adipose tissue, spleen and thymus. In the latter two organs,
UCP2 expression probably re£ects mainly the contribution by
tissue macrophages, as has been documented in liver of adult
rats (where only non-parenchymal, mainly Kup¡er cells, ex-
press UCP2; hence UCP2 expression in liver is very low [10]).
UCP3 is preferentially expressed in skeletal muscle and brown
fat [6,8].
All three UCPs are likely to be involved in the control of
total energy balance. However, their contribution may di¡er
depending on the type of diet [5], environmental temperature
[11], di¡erential expression of UCPs in various tissues (see
above), and also complex hormonal control of their expres-
sion [2,3,9,12,13]. Thus, both UCP1 and UCP3 are likely to be
primarily the mediators of adaptive, hormonally induced ther-
mogenesis [8,9,11,14]. UCP2 might be involved in diet-in-
duced thermogenesis [5] and also in the control of reactive
oxygen species production [15].
In order to better assess the physiological roles of UCPs,
their expression during perinatal development should also be
characterised. Analysis of UCP1 in various animal species
[16^19] clearly indicated a link to perinatal recruitment of
brown fat thermogenesis. We now report that induction of
UCP2 gene expression in various tissues can be detected prior
to the appearance of UCP1 in brown fat. Expression of UCP2
was much stronger in foetal liver than after birth, and, as in
adults, it was restricted to developing macrophages. Our data
suggest that UCP2 may be important for di¡erentiation and
function of the cells of the haematopoietic system.
2. Materials and methods
2.1. Animals and tissues
Experiments were performed on the C57BL/6J mice and Wistar
rats. The animals were kept in a controlled environment (20‡C; 12
h light/dark cycle) with free access to water and standard chow diet.
Tissues and organs (liver, brain, lung, kidney, heart, interscapular
brown fat, colon, placenta, hind leg and spleen) were dissected from
foetuses obtained by Caesarean section between 10 and 19 days of
gestation (d 10^d 19), or from pups which remained with their moth-
ers for 1 h^21 d after spontaneous delivery. Animals were killed by
cervical dislocation under diethylether anaesthesia.
2.2. RNA analysis
Total RNA was isolated [20] from tissue samples stored in liquid
nitrogen, and gene expression was analysed by Northern blots [21],
using the full-length cDNA probes for the mouse UCP1 [22], the
mouse UCP2 and the rat UCP3 genes (see Acknowledgements) and
the 682-bp EcoRI fragment derived from the human liver subunit IV
of mitochondrial cytochrome oxidase (COX IV) gene (ATCC, Rock-
ville, MD, USA). Radioactivity was evaluated by PhosphorImager SF
(Molecular Dynamics). The blots were rehybridised with the 1400-bp
SalI-MluI restriction fragment of the ribosomal 18S cDNA, and the
signal was used to correct for small intersample variations.
2.3. Immunohistochemistry
Mouse liver samples were ¢xed (3 h) in 4% paraformaldehyde-PBS,
dehydrated and para⁄n embedded. Sections (5 mm) were incubated
for 1 h at room temperature in medium containing ¢rst antibodies,
diluted in Dako antibody diluent to reduce background. The batch of
sheep anti-rat UCP1 IgG (1:400 dilution in single labelling, 1:200 in
double labelling) used to detect UCP antigens was described previ-
ously [10]. Second antibodies coupled to alkaline phosphatase (goat
anti-sheep, 1:100 dilution, Sigma Chemical Co.) were visualised using
BCIP/NBT (Dako). Endogenous alkaline phosphatase activity was
inhibited by levamisole (Dako) and endogenous peroxidase activities
by hydrogen peroxide blocking reagent (Dako). With the double la-
belling method, UCP2 was revealed using peroxidase-conjugated anti-
bodies (goat anti-sheep, 1:100, Sigma Chemical Co.) with AEC sub-
strate chromogen (Dako). Antiserum against F4/80 was used as a
marker for the monocyte/macrophage lineage [23] (Biosource Interna-
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tional, 1:40) with rabbit anti-rat IgG (1:100) coupled to alkaline
phosphatase used as second antibodies. Slides were counterstained
with nuclear red or methyl green (single or double labelling, respec-
tively). Control experiments were performed using puri¢ed IgG and
yielded no staining.
2.4. Statistical analysis
Statistical analysis was performed using Student’s t-test. All tests
were judged to be signi¢cant at P6 0.05 (see legend to Fig. 3).
3. Results
3.1. The UCP2 gene is highly expressed in foetal liver
In order to characterise the tissue-speci¢c pattern of UCP2
expression in mouse foetuses, Northern blot analysis was per-
formed with total RNA isolated from di¡erent tissues dis-
sected at the indicated age (Fig. 1). Foetal expression (d 15^
d 19) of the UCP2 gene was found in all tissues analysed (Fig.
1A). Surprisingly, a much stronger signal was detected in foe-
tal liver compared to the livers of 3-week-old (Fig. 1A) or
adult mice [5,8]. Also in murine lung, the levels of UCP2
gene transcript were relatively high, but they did not change
during development (not shown). In contrast to UCP2, ex-
pression of the UCP1 and UCP3 genes could not be detected
in liver, either pre- or postnatally, while both transcripts were
present in brown fat (Fig. 1B,C). The UCP3 probe also hy-
bridised with UCP1 transcript in brown fat (Fig. 1C), and
possibly with the UCP2 gene transcript in foetal liver (Fig.
1C; the faint band between 18S and UCP1 transcripts ; see
also [8]). As a marker of mitochondrial oxidative capacity in
di¡erent tissues, expression of the gene for nuclearly encoded
COX IV was also characterised. Expression of the COX IV
gene did not correlate with that of UCP2, the former being
highest in brown fat relative to other tissues (Fig. 1A).
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Fig. 1. Northern blot analysis of gene expression in mouse (20-Wg sample of total RNA was loaded in each lane). A: After hybridisation with
a mixture of cDNA probes for mouse UCP2 (1.7-kbp transcript), and human COX IV (0.9-kbp transcript), the blot was reprobed for 18S ribo-
somal RNA (18S). All the samples were isolated from foetal tissues at indicated days of gestation, except for the sample isolated from liver of
a 3-week-old pup. B: Hybridisation of mouse UCP1 cDNA (1.4-kbp transcript) with RNA samples from brown fat of adult mouse, and liver
during development (adult mice, 3-week-old pup, and fetuses at d 15^d 19). C: Rat UCP3 cDNA probe detected UCP3 (2.5-kbp) and UCP1
(1.4-kbp) gene transcripts in the samples as in B (the 18S ribosomal RNA probe was also used).
Fig. 2. Northern blot analysis of gene expression in rat. Total RNA
was isolated from spleen and liver of foetal (d 17) and adult rats.
Transcripts for UCP2 and COX IV were detected as in Fig. 1A.
Two parts of the same blot are shown. This ¢gure is representative
of several independent experiments.
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The levels of UCP2 transcripts in foetal rat livers (Fig. 2)
were similar to those in spleen, the organ showing the stron-
gest expression in adult mice and humans [8,9]. As in mice,
the abundance of UCP2 transcripts in rat liver decreased con-
siderably between the foetus and adult (see also [6,9,10] and
[5,7^9] for expression in adult rats and humans, respectively).
However, in contrast to liver, no di¡erences could be observed
in UCP2 expression in foetal and adult rat spleens (Fig. 2).
The results indicate a speci¢c developmental pattern of UCP2
expression in liver.
3.2. Quanti¢cation of UCP2 and COX IV genes expression
during development
To characterise the changes in UCP2 and COX IV gene
expression during perinatal development, samples of whole
body homogenates (Fig. 3A), liver (Fig. 3B,C) and brain
(Fig. 3B,C) were analysed starting from d 10 (whole body
homogenate, up to 4 h after birth) or d 15 of gestation (liver
and brain, until 3 weeks or 5 days after birth, respectively). In
whole foetus homogenates, expression of both genes could be
detected at the earliest gestational period studied (d 10). How-
ever, while approximately a threefold stimulation of UCP2
gene expression was observed between d 10 and d 15 of ges-
tation (with no further changes following d 15 until birth),
expression of the COX IV gene remained relatively stable
during the entire period.
In the liver at d 15, UCP2 gene expression was about four-
fold higher (Fig. 3B) than that measured in the whole body
homogenate (Fig. 3A), and it remained relatively stable pre-
natally. Regarding its relatively large size, it is apparent that
the liver is the major site of foetal UCP2 gene expression.
UCP2 expression started to decline 1 h after birth, reaching
the lowest levels in the 3-week-old pups (the levels about one
order of magnitude lower compared to foetal levels, but still
about threefold higher compared with adult mice; not
shown). A postnatal decline in COX IV gene expression was
also observed (Fig. 3C). However, this decline was relatively
low (approximately twofold), and occurred faster (within the
¢rst postnatal hours) compared with that of UCP2. It is ap-
parent that the changes of UCP2 expression and that of mi-
tochondrial oxidative capacity (COX IV gene expression) oc-
cur independently during the perinatal development.
UCP2 gene expression in brain (Fig. 3B) was signi¢cantly
lower than in whole body homogenate (Fig. 3A) and liver
(Fig. 3B); and it remained stable during development. Also
COX IV gene expression in the brain remained relatively con-
stant (Fig. 3C).
3.3. Immunohistochemical analysis
As before [10], in the absence of either UCP1 or UCP3
transcripts (Fig. 1), the cell type expressing UCP2 in foetal
liver could be identi¢ed using the anti-UCP1 antibodies which
presumably cross-reacted with UCP2 [10]. Immunohistochem-
istry experiments performed on foetal liver (d 16) revealed
highly positive UCP2 cells in non-parenchymal cells but not
in hepatocytes (Fig. 4, part 1a, 1b). Most of the labelled cells
had a sinusoid localisation. These cells were also labelled by
F4/80 antibodies (Fig. 4, part 1bc). Taken together, these data
suggest that the UCP immunoreactive cells belonged to the
monocyte/macrophage lineage [23]. However, it was notewor-
thy that not all the F4/80-positive cells were labelled by anti-
UCP1 antibodies. At 3 d after birth, UCP2-positive cells were
not intensely stained and poorly contrasted with the pink
counterstain (Fig. 4, part 2a). Closer examination (Fig. 4,
part 2b) showed that the cells were less stained than in foe-
tuses (Fig. 4, part 1b).
4. Discussion
The principal ¢nding of this report is the strong expression
of UCP2 gene in foetal liver, and its speci¢c developmental
pattern in this organ. Similarly to adults [10], cells expressing
UCP2 in foetal liver belong mostly to the monocyte/macro-
phage lineage.
The liver is an organ where mitochondrial biogenesis and
function change abruptly at parturition, resulting in a switch
from foetal glycolysis to postnatal oxidative phosphorylation
(for references see [24,25]). An alteration in mitochondrial
function could result from changes in proton conductivity of
the inner mitochondrial membrane [25]. Therefore, the devel-
opmental pattern of UCP2 expression in liver (and the ab-
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Fig. 3. Expression of UCP2 and COX IV mRNA during mouse
perinatal development. A: Expression of UCP2 (b) and COX IV
(a) in whole foetus or newborn body homogenate. B: Expression of
UCP2 gene in liver (b) and brain (a). C: Expression of COX IV
gene in liver (b) and brain (a). Samples from several foetuses or
newborns (n = 4^5) were subjected to Northern blot analysis (see
Fig. 1). Transcripts for UCP2 and COX IV (detected as in Fig. 1A)
were expressed relative to that of 18S ribosomal RNA (see Section
2). Data are means þ S.E. All the di¡erences in UCP2 mRNA levels
between homogenate and liver, and homogenate and brain, respec-
tively, were signi¢cant. Di¡erences in COX IV mRNA levels be-
tween homogenate and liver (d 15^d 19 of gestation), and brain and
liver (d 15 of gestation^1 h after birth) were also signi¢cant.
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Fig. 4. Immunohistochemical detection of UCP antigen in slices of mouse foetal (d 16) liver (1a, 1b, 1bc) and 3-day-old mouse liver (2a, 2b).
Immunostaining was performed using sheep anti-rat UCP1 IgG (1:400 and 1:200 dilution for parts 1 and 2 respectively). 1a, 1b, 2a, 2b: Detec-
tion of UCP-positive cells by single labelling. Dark blue precipitates indicate BCIP/NBT deposit following alkaline phosphatase reaction. Coun-
terstain is nuclear red. 1bc: Double localisation of UCP2 and F4/80 in mouse foetal liver (d 16). Red cytoplasmic precipitates indicate UCP2
localisation by AEC deposit following immunoperoxidase reaction. Dark blue peripheral precipitates indicate in this experiment the presence of
the membraneous F4/80 antigen by BCIP/NBT deposit following alkaline phosphatase reaction. Counterstain is methyl green. a: magni¢cation
U320, bar = 10 Wm; b: magni¢cation U800, bar = 10 Wm.
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sence of either UCP1 or UCP3; see Fig. 1) suggested that
UCP2 could be involved. However, UCP2 was not expressed
in hepatocytes, but only in cells contributing very little (see
Fig. 4) to the hepatic cell pool (i.e. F4/80-positive cells).
Therefore, it is unlikely that UCP2 is the key element control-
ling the changes of mitochondrial energetics in liver during
perinatal development. Thus, the mechanism by which mito-
chondrial energetics is regulated in liver during perinatal de-
velopment will require further clari¢cation.
The physiological role of UCP2 is not known yet with cer-
tainty. Our results clearly demonstrate that UCP2 is expressed
in various tissues of the foetus and that this expression occurs
much earlier than that of UCP1 in brown fat (where UCP1 is
the marker of the thermogenic function, and appears around
d 19 in mice and rats; see [16]). Early recruitment of the
UCP2 gene suggests that the main role of UCP2, at least
during intrauterine development, is not related to thermogen-
esis (see also [26]). The di¡erential expression of UCP2 during
development in tissues rich in macrophages is especially strik-
ing: only in liver does strong expression occur in the foetus
and declines postnatally, while in spleen and lung no changes
could be detected during the perinatal period. This di¡erence
may be related to the role of foetal liver in haematopoiesis,
and migration of this activity to the bone marrow just before
birth (for references see [27,28]). It is inferred that UCP2
might have some role in di¡erentiation and/or function of
the cells of the myelopoietic lineage.
The control of UCP2 expression during liver development is
likely to be quite complex. It might involve hormones which
sharply change their circulating and tissue levels around birth,
such as thyroid hormones [29,30] or insulin [31], or leptin
[32,33] which is released both from adipocytes and from pla-
centa [34]. If thyroid hormones [9] and insulin [35] have no
e¡ect on UCP2 mRNA levels, leptin induces UCP2 gene ex-
pression in lipid-containing cells [13]. The e¡ect of this hor-
mone on early di¡erentiation of the cells of the myelopoietic
lineage in foetal liver has also been demonstrated [28]. It is
probably mediated by the receptor expressed in the haemato-
poietic cells [28,36,37]. Thus leptin may also represent a key
hormone controlling expression of UCP2 in developing mac-
rophages.
In summary, our results indicate that developing monocyte/
macrophage cells in foetal liver represent the major site of
UCP2 gene expression in the foetus. They suggest a role of
UCP2 in di¡erentiation of the myelopoietic lineage and thus
in immune system development.
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